Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Staphylococcus aureus | Peptide deformylase | Starlite/ChEMBL | References |
Streptococcus pneumoniae serotype 4 (strain ATCC BAA-334 / TIGR4) | Peptide deformylase | Starlite/ChEMBL | References |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Trypanosoma cruzi | hypothetical protein | Peptide deformylase | 183 aa | 155 aa | 22.6 % |
Trichomonas vaginalis | abca6, putative | Peptide deformylase | 183 aa | 162 aa | 25.3 % |
Loa Loa (eye worm) | adipor-like receptor | Peptide deformylase | 203 aa | 163 aa | 23.9 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Plasmodium vivax | peptide deformylase, putative | 0.0558 | 1 | 0.5 |
Echinococcus multilocularis | cyclin g associated kinase | 0.0145 | 0.0353 | 0.5 |
Mycobacterium tuberculosis | Probable polypeptide deformylase Def (PDF) (formylmethionine deformylase) | 0.0558 | 1 | 0.5 |
Mycobacterium leprae | PROBABLE POLYPEPTIDE DEFORMYLASE DEF (PDF) (FORMYLMETHIONINE DEFORMYLASE) | 0.0558 | 1 | 0.5 |
Wolbachia endosymbiont of Brugia malayi | peptide deformylase | 0.0558 | 1 | 0.5 |
Loa Loa (eye worm) | NAK/GAK protein kinase | 0.0145 | 0.0353 | 1 |
Schistosoma mansoni | serine/threonine protein kinase | 0.0145 | 0.0353 | 0.5 |
Trypanosoma cruzi | Peptide deformylase 2, putative | 0.0213 | 0.1931 | 0.5 |
Trypanosoma cruzi | Peptide deformylase 2, putative | 0.0213 | 0.1931 | 0.5 |
Trypanosoma brucei | Polypeptide deformylase 1 | 0.0213 | 0.1931 | 0.5 |
Trypanosoma cruzi | polypeptide deformylase-like protein, putative | 0.0213 | 0.1931 | 0.5 |
Trypanosoma cruzi | polypeptide deformylase-like protein, putative | 0.0213 | 0.1931 | 0.5 |
Trypanosoma brucei | Peptide deformylase 2 | 0.0213 | 0.1931 | 0.5 |
Brugia malayi | Protein kinase domain containing protein | 0.0145 | 0.0353 | 0.5 |
Mycobacterium ulcerans | peptide deformylase | 0.0558 | 1 | 0.5 |
Echinococcus granulosus | cyclin g associated kinase | 0.0145 | 0.0353 | 0.5 |
Treponema pallidum | polypeptide deformylase (def) | 0.0558 | 1 | 0.5 |
Toxoplasma gondii | hypothetical protein | 0.0558 | 1 | 0.5 |
Plasmodium falciparum | peptide deformylase | 0.0558 | 1 | 0.5 |
Leishmania major | polypeptide deformylase-like protein, putative | 0.0213 | 0.1931 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
IC50 (binding) | = 0.31 nM | Inhibition of Streptococcus pneumoniae PDF assessed as formate release from fMAS peptide substrate after 20 mins by formate dehydrogenase coupled assay | ChEMBL. | 22579486 |
IC50 (binding) | = 1.6 nM | Inhibition of Staphylococcus aureus PDF assessed as formate release from fMAS peptide substrate after 20 mins by formate dehydrogenase coupled assay | ChEMBL. | 22579486 |
Stability (ADMET) | = 99.7 % | Metabolic stability of the compound in human blood assessed as compound remaining at 2000 ng/mL after 2 hrs | ChEMBL. | 22579486 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.